Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Biorg Med Chem 25:61806189 Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg M, Ramaswamy B, Fowler J, Wei L et al (2019) Phase I immunotherapy trial with two chimeric HER-2 B-cell peptide vaccines emulsified in montanide ISA 720VG and nor-MDP adjuvant in patients with advanced solid tumors phase I immunotherapy trial with two B-cell vaccines
Long-Term Safety Evidence While many peptide therapies have been evaluated only in short-term trials, AOD-9604 benefits from long-term safety data extending to 24 weeks of continuous administration
Below are some commonly observed symptoms
Figure 2: Changes in rotation asymmetry expressed as the percentage of the animals rotation in the direction of the damage relative to rotations in both directions
US$ 26.03
US$ 29.88
US$ 28.35
